Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

307
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
307
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

434
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
434
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

275
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
275
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

328
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
328
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

120
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
120
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.8K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Blood neoplasia·2026
Same author

Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups.

JCO clinical cancer informatics·2026
Same author

FDA approvals for pediatric cancer indications using children's oncology group associated trials data.

Journal of the National Cancer Institute·2026
Same author

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors.

Pediatric blood & cancer·2026
Same author

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study.

Pediatric blood & cancer·2026
Same author

A Quality Improvement Initiative: Increasing Awareness of Long-Term Follow-Up Care in Pediatric Cancer Survivors and Caregivers.

Journal of pediatric hematology/oncology·2026

Related Experiment Video

Updated: Mar 12, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Using a Bedside Algorithm to Individually Dose High-dose Methotrexate for Patients at Risk for Toxicity.

Jennifer H Foster1, Melanie B Bernhardt, Patrick A Thompson

  • 1*Baylor College of Medicine †Texas Children's Hospital, Houston, TX ‡University of North Carolina, Chapel Hill, NC.

Journal of Pediatric Hematology/Oncology
|November 8, 2016
PubMed
Summary

A new bedside algorithm safely adjusts high-dose methotrexate (HDMTX) for acute lymphoblastic leukemia patients, preventing toxicity without dose reduction. This personalized approach ensures effective treatment for at-risk individuals.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K

Related Experiment Videos

Last Updated: Mar 12, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • High-dose methotrexate (HDMTX) is crucial for treating acute lymphoblastic leukemia (ALL).
  • Patients receiving HDMTX are at risk of severe toxicities, necessitating careful dose management.
  • Current protocols may involve preinfusion dose reductions, potentially compromising efficacy.

Purpose of the Study:

  • To develop and evaluate a bedside algorithm for individualized HDMTX dose adjustment in high-risk ALL patients.
  • To assess the safety and efficacy of the algorithm in preventing methotrexate toxicity.
  • To determine if the algorithm obviates the need for routine preinfusion dose reduction.

Main Methods:

  • A retrospective review of 8 patients who received 21 cycles of HDMTX using the developed algorithm.
  • Comparison of cycles initiated at full dose (5 g/m) versus those with a 20%-25% preinfusion dose reduction.
  • Analysis of methotrexate area under the curve (AUC), steady-state plasma concentration (Cpss), and toxicity profiles.

Main Results:

  • No statistically significant differences were observed in mean MTX AUC or mean Cpss between the full-dose and reduced-dose groups.
  • The algorithm facilitated safe administration of HDMTX in patients identified as high-risk for toxicity.
  • Toxicities were not significantly different between the groups, indicating comparable safety profiles.

Conclusions:

  • The developed bedside algorithm enables safe and individualized administration of HDMTX in ALL patients.
  • The algorithm effectively manages methotrexate toxicity risk without compromising therapeutic drug exposure.
  • This approach supports optimized HDMTX dosing, potentially improving treatment outcomes for high-risk ALL patients.